Infliximab treatment of severe genital ulcers associated with Behçet disease.
Kasugai
Chikatoshi
C
Department of Dermatology, Aichi Medical University, Aichi, Japan.
Watanabe
Daisuke
D
Department of Dermatology, Aichi Medical University, Aichi, Japan. Electronic address: dwatanab@aichi-med-u.ac.jp.
Mizutani
Kimihiko
K
Department of Dermatology, Aichi Medical University, Aichi, Japan.
Masuda
Yuko
Y
Department of Dermatology, Aichi Medical University, Aichi, Japan.
Zako
Masahiro
M
Department of Ophthalmology, Aichi Medical University, Aichi, Japan.
Mukai
Tomoyuki
T
Department of Rheumatology, Aichi Medical University, Aichi, Japan.
Tamada
Yasuhiko
Y
Department of Dermatology, Aichi Medical University, Aichi, Japan.
Matsumoto
Yoshinari
Y
Department of Dermatology, Aichi Medical University, Aichi, Japan.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications*; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D019233:Retreatment; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014456:Ulcer / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069285:Infliximab